May 20, 2015 – Sirona Biochem Corp.
Vancouver, British Columbia – May 20, 2015 –
Sirona Biochem Corp. (TSX-V: SBM)(FSE: ZSB) is pleased to announce that its lead anti-aging compound also shows antioxidant properties in early preclinical studies.
As part of the anti-aging project, the Company has selected several potential lead compounds. One of these, SBM-TFC-837, showed a significant preservative effect against different stressors, such as starvation or ultraviolet radiation. Studies now indicate that SBM-TFC-837 also shows high preservative effect against oxidative stress induced by H2O2.
Oxidative stress response in humans causes free radicals which can damage cells and genetic material. The effect on cells can be degeneration, aging and various disease states. Antioxidants prevent this damage.
â€œAn antioxidant effect on cells is a huge plus for our glycoprotein program for anti-aging,â€ said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. â€œIf aging is the result of oxidative stress that leads to further cell damage, these new results suggest multiple mechanisms by which our glycoproteins exert their protective effects. This discovery will certainly be beneficial to our current partnering discussions.â€
Further studies are ongoing and will continue to assess cell stressors and viability. The compounds may have applications in:
• Anti-aging cosmetic product since 80% of visible aging is directly related to cell death
• Regenerative and protective cosmetic or pharmaceutical product for healing, wound care, hypothermic protection, sunscreen, post burn / radiotherapy
• Regenerative and protective pharmaceutical product against stress response in renal reperfusion and the improvement of engraftment
• Pharmaceutical product used in organ transplantation solution (for example Wisconsin solution)
• Regenerative and preservative product for preservation of stem cells, Î²-islet cells, red blood cells, adipocytes and platelets as well as tissues including reconstituted human epithelial cells, skin explants and cornea
• Preservative for vaccines
The global anti-aging market is forecast to reach up to $345.8 billion US in 2018 from $249.3 billion in 2012. The related market for regenerative medicine, which aims to restore functional ability to tissues and organs, is set to hit $67.6 billion US in 2020.
We would like to acknowledge and thank Bpifrance and the region Haute Normandie for their ongoing support on the anti-aging project
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.